Diurnal Group PLC (LON:DNL)‘s stock had its “buy” rating reissued by equities researchers at Numis Securities Ltd in a research report issued on Wednesday. They presently have a GBX 169 ($2.18) price objective on the stock. Numis Securities Ltd’s price objective would suggest a potential upside of 26.59% from the company’s previous close.

Separately, Panmure Gordon reaffirmed a “buy” rating and set a GBX 178 ($2.30) price target on shares of Diurnal Group PLC in a report on Thursday, June 15th.

Diurnal Group PLC (DNL) remained flat at GBX 133.50 during mid-day trading on Wednesday. The company had a trading volume of 36,837 shares. Diurnal Group PLC has a 12 month low of GBX 105.00 and a 12 month high of GBX 143.50. The firm has a 50 day moving average of GBX 132.07 and a 200-day moving average of GBX 130.20. The firm’s market cap is GBX 69.70 million.

Diurnal Group PLC (LON:DNL) last issued its quarterly earnings results on Tuesday, October 10th. The company reported ($0.18) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.24) by $0.06.

COPYRIGHT VIOLATION WARNING: This article was first published by American Banking News and is owned by of American Banking News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/09/10/diurnal-group-plcs-dnl-buy-rating-reiterated-at-numis-securities-ltd.html.

In other news, insider John Goddard purchased 10,791 shares of the business’s stock in a transaction dated Thursday, September 7th. The stock was bought at an average price of GBX 5 ($0.06) per share, with a total value of £539.55 ($696.82).

About Diurnal Group PLC

Diurnal Group plc is a clinical-stage pharmaceutical company. The Company is engaged in developing hormone therapeutics to aid treatment for various endocrine conditions. The Company’s products include Chronocort, which is engaged in developing hydrocortisone product for the treatment of congenital adrenal hyperplasia and adrenal insufficiency; Infacort, which is engaged in creating paediatric hydrocortisone replacement product for neonates and infants suffering from adrenal insufficiency; Native Oral Testosterone, which is engaged in creating oral testosterone treatment for hypogonadism, and Tri4Combi, which is engaged in developing combination therapy product of thyroid hormones for patients suffering from hypothyroidism.

Receive News & Ratings for Diurnal Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diurnal Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.